This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Achillion Pharmaceuticals, Inc.
Drug Names(s): ACH-2928
Description: ACH-2928 is an NS5A inhibitor that has demonstrated potency against HCV RNA replication in all all genotypes. ACH-2928 was shown to be effective in combination with NS3 protease inhibitors, NS5B polymerase inhibitors, interferon and ribavirin in replication assays.
Achillion is also developing a second generation NS5A inhibitor, ACH-3102.
Additional information available to subscribers only: